Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

  • Sorrento Therapeutics, Inc. SRNE shares dipped 22.3% to $0.7301 in pre-market trading. Sorrento Therapeutics’ Subsidiary Scilex acquired rights to FDA-approved ELYXYB in the US and Canada for the acute treatment of migraine.
  • Citius Pharmaceuticals, Inc. CTXR declined 7.1% to $1.30 in pre-market. Citius Pharmaceuticals posted a Q1 loss of $0.02 per share.
  • Fate Therapeutics, Inc. FATE fell 4.5% to $5.94 in pre-market trading. HC Wainwright & Co, last month, downgraded Fate Therapeutics from Buy to Neutral and lowered the price target from $115 to $7.
  • Hesai Group HSAI dropped 4.3% to $21.25 in pre-market trading. Hesai Group recently priced its IPO at $19 per ADS.

Don’t forget to check out our premarket coverage here

  • Virgin Orbit Holdings, Inc. VORB fell 3.6% to $1.59 in pre-market trading after gaining 6% on Friday. Virgin Orbit and Poland-based satellite manufacturer SatRev recently reported a follow-on launch services agreement (LSA) for additional launches of SatRev's satellites in 2023 and beyond.
  • New Oriental Education & Technology Group Inc. EDU fell 3.6% to $38.38 in pre-market trading. New Oriental Education, last month, posted mixed quarterly results.
  • ZIM Integrated Shipping Services Ltd. ZIM declined 3.4% to $21.70 in pre-market trading. ZIM Integrated Shipping Services, during November, reported better-than-expected Q3 EPS and sales results.

Now Read This: https://www.benzinga.com/news/earnings/23/02/30871643/investor-optimism-declines-as-dow-records-weekly-loss

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksSmall CapPre-Market OutlookMarketsMoversTrading Ideasbig losersTop Losers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!